While recombinant protein vaccines based on Sm-TSP-2-EC2 have shown immunogenicity and protection in schistosomiasis preclinical challenge models, further improvements in efficacy may still be achieved for optimal protective outcomes. This evidence concerns the gene THBS2 and schistosomiasis.